CN1168803A - 一种治疗癌症白红细胞血小板降低的中成药 - Google Patents
一种治疗癌症白红细胞血小板降低的中成药 Download PDFInfo
- Publication number
- CN1168803A CN1168803A CN 97108606 CN97108606A CN1168803A CN 1168803 A CN1168803 A CN 1168803A CN 97108606 CN97108606 CN 97108606 CN 97108606 A CN97108606 A CN 97108606A CN 1168803 A CN1168803 A CN 1168803A
- Authority
- CN
- China
- Prior art keywords
- chinese patent
- patent medicine
- blood
- platelet reduction
- blood platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 210000001772 blood platelet Anatomy 0.000 title claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 18
- 201000011510 cancer Diseases 0.000 title claims abstract description 17
- 230000009467 reduction Effects 0.000 title claims abstract description 12
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- 239000000945 filler Substances 0.000 claims abstract description 3
- 239000007787 solid Substances 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- 241000726221 Gemma Species 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001415959 Grus japonensis Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- -1 sheet Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种治疗癌症白红细胞血小板降低的中成药,包括组分:仙鹤草、补骨脂、赤小豆、鸡血藤、黄精、当归、生山楂、甘草。经加工制成液体的口服液中成药。也可以再经浓缩或稀释或者增加赋形填充剂,制成各种固体剂型的中成药。本发明不仅可以同时提升白细胞、红细胞、血小板,也可以抗癌治癌。成批工业化生产容易,且成本和成品价格低,患者易承受。临床选用或患者服用均很方便。临床实验表明五天一个疗程,总显效率达98%。
Description
本发明属于祖国中成药,尤其是涉及一种治疗癌症白红细胞血小板降低的中成药。
对癌症患者主要用放疗和化疗的治疗方法,但放化疗之后,人体白细胞、红细胞、血小板即三系细胞明显下降,临床上呈现出放化疗不良反应和付作用,不得不终止放化疗,继而采用各种提升白细胞的药物。例如,西药升白欣注射剂促进人体白细胞增多。这类药物的不足:一是仅以促进白细胞增多素为主要成分,不能同时提升、红细胞、血小板。二是注射用药,患者不能自行使用。三是价格昂贵。中国发明专利公开号CN1106287A,公开了一种升血宝颗粒剂中成药,克服了注射用药的不便,具有价格低的特点,可实现升高血细胞,但疗程时间长,一个疗程需21天。
本发明的目的是提供一种治疗癌症白红细胞血小板降低的中成药,一是对放化疗或其它原因产生的三系细胞降低应同时得到提升,并在较短疗程时间内迅速恢复和维持人体所需正常范围内,使放化疗得以正常进行。二是同时还兼具有治疗癌症的作用,即提升三系细胞和治疗癌症作用于一体。三是多种中成药剂型供医生临床选用,且患者遵医服用方便。四是成本和价格低。
本发明的目的是采用下述技术方案实现的:
一种治疗癌症白红细胞血小板降低的中成药,其特殊之处在于包括组分,仙鹤草、补骨脂、赤小豆、鸡血藤、黄精、当归、生山楂、甘草,经加工制成浓缩或稀释的液体口服液或固体的中成药。
本发明与现有技术相比所具有的有益效果;
1.根据本发明的技术方案中医药理分析:
(1)仙鹤草:性味苦、酸、平。入肺肝脾经。收敛止血,消炎止痢,理跌打伤,散疮毒。能缩短凝血时间,使血小板计数增加,促进血浆凝血活酶的生成,增加细胞的抵抗力,降低血糖,并对金黄色葡萄球菌、绿脓杆菌、伤寒杆菌有抑制作用。
(2)补骨脂:性味辛、温、入肾经。主五劳七伤,风虚冷,骨髓伤败,治肾泄,通命门,暖丹田,敛精神,补肾助阳。止血作用明显,舒张平滑肌,抑制金黄色葡萄球菌,有抗癌作用。
(3)赤小豆:性味甘、酸、平。归心、小肠经。利水除湿,清热消肿和血,主下水,排痈肿脓血、疮疡肿毒。解热毒,补血脉,对细菌有抑制作用。
(4)鸡血藤:性味甘、平、微温。入肝肾经。补血活血,舒筋通络,去瘀血、生新血、流利经脉。对金黄色葡萄球菌有抑制作用。
(5)黄精:性味甘、平。归脾肺肾经。补脾润肺,补中益气养阴。除风湿,安心血,平补气血,补虚添精。作用于心血管系统,增加冠脉血流量,降血压,抗病原微生物,降低血糖。
(6)当归:性味甘、辛、温。入心肝脾经。补血和血,调经止痛,润燥滑肠,治诸恶疮疡。有较强的镇静止痛作用,抑制血小板聚集,抗贫血作用。对溶血性链球菌、伤寒杆菌、大肠杆菌有抑菌作用。可明显降低体温,对平滑肌有明显的松驰作用。有增强腹腔巨噬细胞吞噬能力。
(7)生山楂:性味酸、甘、微温。归脾胃肝经。消食积、散瘀血,治滞血痛胀。作用于心血管系统,化血块、气块,活血、降血脂,抗菌。
(8)甘草:性味甘、平、微温。入十二经。泻火解毒,活血润肺止咳,补脾缓急,调和诸药。主五脏六腑寒热邪气,坚筋骨,长肌肉倍力气,通经脉,利血气,解百药毒。
对本发明技术方案中医药理综合分析:祖国医学认为“人之百病,皆由于气,气血不调,百病丛生,正气内存,邪不可干,邪之所凑,其气必虚”。致癌因素侵入人体,由于气血不调而使机体不能清除而存入体内,一旦机体在各种致病因素作用下,局部组织的细胞异常增生而导致发病。在肿瘤治疗中由于采用放化疗法杀除癌变细胞,同时也使正常白、红细胞、血小板明显降低,而出现各种不良反应和付作用。为此针对三系细胞降低或失衡及癌症治疗,经过多种组分筛选、分析、试制和临床实验研究,提出了选用具有抗菌补血、抗癌止血的仙鹤草、补骨脂等天然植物,加工提纯而成。药理综合分析;是以仙鹤草补血增加细胞抵抗力、补骨脂补肾助阳抗癌止血为“君”。“臣”以当归补血和血,增加巨噬细胞吞噬能力,赤小豆利水除湿,黄精补中益气。“佐”以鸡血藤补血活血、舒筋通络,生山楂活血化瘀。“使”以甘草补脾益气和中。这样“君臣佐使”协同作用,相辅相承,共同调整脏腑气血、补血活血,调节人体自身免疫能力,加强和恢复人体自身造血功能,抗癌解毒,扶正固本。因此本方案不仅可以同时提升三系细胞,也可以抗癌治癌。
2.根据临床试验分析:
临床试验观察150例,其中诊断分类为肺癌70例、乳腺癌40例、恶性淋巴癌35例、食管癌3例,其它原因所致贫血2例。经放化疗后患者均出现多种不良反应和付作用,贫血貌竞有94例。经临床内服本发明的中成药,对四肢无力、疲倦、呕吐、厌食等症状在48小时即可缓解,对三系细胞降低的患者,在五天一个疗程内,三系细胞由用药前、后提升对比情况见下表。
用本药前后三系细胞提升对比表
三系细胞 | 用本药前 | 用本药后 |
白细胞(WBc) | 2.35±0.775×109/L | 4.8±0.46×109/L |
红细胞(RBc) | 3.92±0.42×1012/L | 5.13±0.63×1012/L |
血小板(PIT) | 89.6±0.46×109/L | 130.8±0.87×109/L |
血红蛋白(HcB) | 119.16±0.48g/L | 138.5±0.21g/L |
初效时间2-3天,平均显效时间为五天。三系细胞提升迅速且显著的占78%,提升有效的占20%,无效的占2%,总显效率98%。在临床上已经使用其它同类药物无效的患者,改用本药后三系细胞仍可得到正常的提升。
本药经急毒检验,测得对实验小鼠相当于原生药的最大耐受量为临床实际用量的40倍,因此临床用药量是安全的。
3.本发明技术方案所选用的中药组分是常见中草药,成本低。成批工业化生产容易。成品价格低,患者易承受。产品可以有液体、固体等不同剂型,医生临床选用或患者遵医服用均很方便。
综上所述本发明的技术方案可以取得有益的效果。
结合实施例进一步详细说明本发明技术方案:
一种治疗癌症白红细胞血小板降低的中成药,包括各中药组分及最佳含量的重量百分比为:仙鹤31.0% 补骨脂7.0% 赤小豆17.1% 鸡血藤10.3% 黄精10.3% 当归7.0% 生山楂10.3% 甘草7.0%上述各中药组分总重量为百分之百。按上述比例选配中药原料,置于提取锅内,加水煎煮两次,并将两次煎煮的药液混合过滤,再加入等量的纯度95%的乙醇,再次过滤后加入红糖粉搅拌混匀过筛,最后经分装制得剂型为液体的口服液中成药。也可以再经浓缩或稀释或者增加赋形填充剂,制成丸、散、粉、颗粒、片、胶囊等各种固体剂型的中成药。
本发明一种治疗癌症白红细胞血小板降低的中成药,于1997年6月10日委托陕西省科学技术信息研究所查新,1997年6月13日出证《科学技术项目查新报告(第97182)》。检索查新结果指出:未见与一种治疗癌症白红细胞血小板降低的中成药方剂相同的药品文献报导。
Claims (4)
1.一种治疗癌症白红细胞血小板降低的中成药,其特征是包括组分:仙鹤草、补骨脂、赤小豆、鸡血藤、黄精、当归、生山楂、甘草,经加工制成。
2.根据权利要求1所述的一种治疗癌症白红细胞血小板降低的中成药,其特征是各中药组分含量的重量百分比为:仙鹤草3-60%补骨脂1-15%赤小豆1-35%鸡血藤1-25%黄精 1-25%当归 1-15%生山楂1-25%甘草 1-15%上述各中药组分总重量为百分之百。
3.根据权利要求1或权利要求2所述的一种治疗癌症白红细胞血小板降低的中成药,其特征是各中药组分最佳含量的重量百分比为:仙鹤草31.0%补骨脂7.0%赤小豆17.1 鸡血藤10.3%黄精 10.3%当归 7.0%生山楂10.3% 甘草 7.0%
上述各中药组分总重量为百分之百。
4.根据权利要求1所述的一种治疗癌症白红细胞血小板降低的中成药,其特征是:还包括赋形填充剂,产品剂型可以是液体的口服液或固体的中成药。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97108606A CN1065754C (zh) | 1997-06-16 | 1997-06-16 | 一种治疗癌症白红细胞血小板降低的中成药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97108606A CN1065754C (zh) | 1997-06-16 | 1997-06-16 | 一种治疗癌症白红细胞血小板降低的中成药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1168803A true CN1168803A (zh) | 1997-12-31 |
CN1065754C CN1065754C (zh) | 2001-05-16 |
Family
ID=5170551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97108606A Expired - Fee Related CN1065754C (zh) | 1997-06-16 | 1997-06-16 | 一种治疗癌症白红细胞血小板降低的中成药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1065754C (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049827A (zh) * | 1989-08-29 | 1991-03-13 | 杨春砚 | 回收饮食玻璃包装物的清洁消毒方法 |
CN1048165A (zh) * | 1990-03-05 | 1991-01-02 | 林志高 | 智力积木 |
CN1110571A (zh) * | 1994-04-27 | 1995-10-25 | 周纯喜 | 一种抗癌治癌药物及其生产工艺 |
CN1097620A (zh) * | 1994-06-04 | 1995-01-25 | 李荣生 | 一种治疗消化道肿瘤的中药制剂 |
-
1997
- 1997-06-16 CN CN97108606A patent/CN1065754C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1065754C (zh) | 2001-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1330347C (zh) | 中药滋补膏 | |
CN104740308B (zh) | 一种医用生物降血糖口服液及其制备方法 | |
CN100457158C (zh) | 增强人体免疫功能的药物 | |
CN102210820A (zh) | 一种治疗白血病的中药组合物 | |
CN1305515C (zh) | 治疗癌症的中药散剂及汤剂组合物 | |
CN101979013B (zh) | 一种治疗白血病的中药 | |
CN109105587A (zh) | 具有增强免疫力缓解疲劳作用的袋泡茶及其制作方法 | |
CN104083728B (zh) | 抗癌消瘤浓缩丸的加工方法 | |
CN1065754C (zh) | 一种治疗癌症白红细胞血小板降低的中成药 | |
CN102861236B (zh) | 一种纯中药抗肿瘤制剂 | |
CN104738273A (zh) | 一种有助于提高机体免疫力的食药同源养生茶配方 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102512593B (zh) | 一种治疗再生障碍性贫血症的中药制剂 | |
CN101485716A (zh) | 一种治疗放射损伤药物及其制备方法 | |
CN112076305A (zh) | 一种治疗人体代谢症候群及杀菌消炎的中药制内服外用原液合剂 | |
CN108355052A (zh) | 一种治疗放化疗后白细胞降低的药物及其制备方法 | |
CN108671116A (zh) | 用于治疗糖尿病的中草药组合物及其制备和服用方法 | |
CN114272344B (zh) | 一种治疗气阴两虚兼血瘀型脏腑功能失调症的中药组合物、制剂与应用 | |
CN114404490B (zh) | 用于治疗肿瘤放化疗后白细胞减少症的中药及制备方法 | |
CN1118262A (zh) | 治癌合剂 | |
CN1077129A (zh) | 奇效食道口服液及其制造方法 | |
CN1054298C (zh) | 一种治疗萎缩性胃炎和食管癌的药剂 | |
CN104758748B (zh) | 一种辅助肿瘤化疗的中药 | |
CN1092969C (zh) | 抗癌扶正中药 | |
CN111603499A (zh) | 一种预防和治疗癌症的中药药物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |